4.8 Article

A PEG-Fmoc conjugate as a nanocarrier for paclitaxel

期刊

BIOMATERIALS
卷 35, 期 25, 页码 7146-7156

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2014.04.108

关键词

Micelle; 9-Fluorenylmethoxycarbonyl; Drug-carrier interaction; Paclitaxel; Drug delivery; Cancer therapy

资金

  1. NIH [R21CA173887, RO1CA174305, R01GM102989]

向作者/读者索取更多资源

We report here that a simple, well-defined, and easy-to-scale up nanocarrier, PEG(5000)-lysyl-(alpha-Fmoc-epsilon-t-Boc-lysine)(2) conjugate (PEG-Fmoc), provides high loading capacity, excellent formulation stability and low systemic toxicity for paclitaxel (PTX), a first-line chemotherapeutic agent for various types of cancers. 9-Fluorenylmethoxycarbonyl (Fmoc) was incorporated into the nanocarrier as a functional building block to interact with drug molecules. PEG-Fmoc was synthesized via a three-step synthetic route, and it readily interacted with PTX to form mixed nanomicelles of small particle size (25-30 nm). The PTX loading capacity was about 36%, which stands well among the reported micellar systems. PTX entrapment in this micellar system is achieved largely via an Fmoc/PTX pi-pi stacking interaction, which was demonstrated by fluorescence quenching studies and C-13 NMR. PTX formulated in PEG-Fmoc micelles demonstrated sustained release kinetics, and in vivo distribution study via near infrared fluorescence imaging demonstrated an effective delivery of Cy5.5-labled PDX to tumor sites. The maximal tolerated dose for PTX/PEG-Fmoc (MTD > 120 mg PTX/kg) is higher than those for most reported PTX formulations, and in vivo therapeutic study exhibited a significantly improved antitumor activity than Taxol, a clinically used formulation of PTX. Our system may hold promise as a simple, safe, and effective delivery system for PTX with a potential for rapid translation into clinical study. (C) 2014 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据